24C Stock Chart & Stats
€3.05
-€0.11(-3.37%)
At close: 4:00 PM EDT
€3.05
-€0.11(-3.37%)
Day’s Range― - ―
52-Week Range€2.18 - €3.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€87.21M
Enterprise Value€1.10B
Total Cash (Recent Filing)€138.20M
Total Debt (Recent Filing)€9.10M
Price to Earnings (P/E)19.4
Beta0.32
Next Earnings
Feb 11, 2027EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.48
Shares Outstanding32,904,050
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.12
Price to Sales (P/S)2.45
P/FCF Ratio21.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)€39.89M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives C-Rad substantial financial flexibility and reduces exposure to interest costs or refinancing pressure. This supports continued investment in SGRT products, software, and customer support while improving resilience if hospital capital spending becomes less predictable.
Improved ProfitabilityMeaningfully improved net income and healthy EBIT margins indicate that the business is currently converting operations into stronger earnings. If maintained, this profitability can fund product development, service capabilities, and market expansion without relying heavily on additional borrowing.
Positive Free Cash FlowPositive operating and free cash flow provide internal funding for the installed-base service model and ongoing technology investment. Although conversion is imperfect, current cash generation gives C-Rad greater capacity to support operations and pursue growth while preserving its low-debt position.
Bears Say
Uneven Revenue GrowthThe modest and uneven revenue trajectory suggests that demand has not yet developed into a consistently strong growth pattern. Continued variability could limit operating leverage and make it harder for C-Rad to compound earnings through broader adoption of its SGRT systems and software.
Inconsistent Cash ConversionCash generation is positive but has not consistently kept pace with accounting earnings, and the company has previously reported negative free cash flow. This reduces the reliability of internally funded growth and makes future investment capacity more dependent on operating improvement.
Margin And Return VolatilityThe sharp swing in margins and lower return on equity compared with earlier periods indicate that recent profitability may not yet be fully sustainable. Persistent volatility could weaken management's ability to plan investment and reduce the earnings benefit of the company's otherwise conservative balance sheet.
C-Rad AB Class B News
24C FAQ
What was C-Rad AB Class B’s price range in the past 12 months?
C-Rad AB Class B lowest stock price was €2.18 and its highest was €3.38 in the past 12 months.
What is C-Rad AB Class B’s market cap?
C-Rad AB Class B’s market cap is €87.21M.
When is C-Rad AB Class B’s upcoming earnings report date?
C-Rad AB Class B’s upcoming earnings report date is Feb 11, 2027 which is in 111 days.
How were C-Rad AB Class B’s earnings last quarter?
C-Rad AB Class B released its earnings results on Oct 22, 2026. The company reported €0.028 earnings per share for the quarter, beating the consensus estimate of €0.027 by <€0.001.
Is C-Rad AB Class B overvalued?
According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued.
Does C-Rad AB Class B pay dividends?
C-Rad AB Class B does not currently pay dividends.
What is C-Rad AB Class B’s EPS estimate?
C-Rad AB Class B’s EPS estimate is 0.03.
How many shares outstanding does C-Rad AB Class B have?
C-Rad AB Class B has 32,904,050 shares outstanding.
What happened to C-Rad AB Class B’s price movement after its last earnings report?
C-Rad AB Class B reported an EPS of €0.028 in its last earnings report, beating expectations of €0.027. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of C-Rad AB Class B?
Currently, no hedge funds are holding shares in DE:24C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
C-Rad AB Class B
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking; and cAccessory, which automates the registration and validation of treatment accessories. Further, it provides SmartPhantom RT, a device that allows automatic adjustment and alignment of fixed lasers with motorization; StaticPhantom, a set-up used to visually verify the precision of the alignment of lasers; high impact technology motorized system, a laser positioning system; HIT Single Diode; and HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
Technical Analysis
AddLife AB
―
Paxman AB
―
RaySearch Laboratories AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―